REDWOOD CITY, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc.(NASDAQ:MNLO) today announced the pricing of the Company’s initial public offering of 7,000,000 shares of common stock at a public offering price of $17.00 per share, before underwriting discounts. All of the...
REDWOOD CITY, Calif., November 21, 2017 /PRNewswire/ — Menlo Therapeutics Inc., a late- stage biopharmaceutical company developing a neurokinin 1 (NK‐1) receptor antagonist (serlopitant) for the treatment of pruritus (itch) and refractory chronic cough, has initiated enrollment in a new Phase 2...
REDWOOD CITY, Calif., October 26, 2017 /PRNewswire/ — Menlo Therapeutics Inc., a clinical stage biopharmaceutical company developing a neurokinin 1 (NK‐1) receptor antagonist (serlopitant) has initiated enrollment in a 170-subject Phase 2 trial evaluating serlopitant as a treatment for...
REDWOOD CITY, Calif., October 17, 2017 /PRNewswire/ — Menlo Therapeutics Inc., a late stage biopharmaceutical company, is developing a neurokinin 1 (NK‐1) receptor antagonist (serlopitant) for the treatment of pruritus (itch) associated with various underlying conditions, and for the treatment...
The Primary Efficacy Endpoint and Multiple Secondary Endpoints of Both Studies Were Met MENLO PARK, Calif., Sept. 18, 2017 /PRNewswire/ — Menlo Therapeutics Inc. announced today the presentation of data from two phase 2 clinical studies of serlopitant at the 2017 EADV conference, the...
venBio leads Series C Financing of oral once-daily Anti-Pruritus Therapy in development for Pruritus of Atopic Dermatitis, Psoriasis and Prurigo Nodularis, and for Refractory Chronic Cough MENLO PARK, Calif., July 18, 2017 /PRNewswire/ — Menlo Therapeutics Inc. announced today that the...
Results Presented at the 2017 Annual Meeting of the American Academy of Dermatology MENLO PARK, Calif., March 8, 2017 /PRNewswire/ — Menlo Therapeutics Inc. announced today that the phase 2 trial (TCP-102) evaluating serlopitant for the treatment of pruritus (itch) associated with prurigo...
MENLO PARK, Calif., Jan. 6, 2017 /PRNewswire/ — Menlo Therapeutics Inc. (“Menlo”) has initiated enrollment in two new Phase 2 trials evaluating a novel neurokinin 1 (NK-1) receptor antagonist, serlopitant, for the treatment of pruritus (itch) associated with atopic dermatitis...
MENLO PARK, Calif., Jan. 5, 2017 /PRNewswire/ — Menlo Therapeutics Inc., a clinical stage pharmaceutical company, is developing a neurokinin 1 (NK-1) receptor antagonist (serlopitant, VPD-737) for the treatment of pruritus (itch). Over the past 16 months, Menlo Therapeutics established...
MENLO PARK, Calif., Aug. 10, 2016 /PRNewswire/ — Menlo Therapeutics Inc., (Menlo Park, CA) announced today that it has entered into an exclusive license agreement with Japan Tobacco Inc. (JT) (TSE:2914) and Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551) for the development and...
